Exelixis Announces EMA Acceptance of Marketing Authorization...
Exelixis, Inc. today announced the European Medicines Agency has accepted for review the Marketing Authorization Application for COMETRIQ for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer .
Join the discussion below, or Read more at Freshnews.
#1 Nov 30, 2012
Looking for more information on Cometriq? Here's a pharmacist's description: http://www.rxwiki.com/cometriq
#2 Dec 13, 2012
We don't have the time to keep up with the current marketing trends. We are looking for a marketing firm grand rapids who is forward thinking. Any recommendations?
Add your comments below
|Lawmakers revisiting requiring those on Medicai...||36 min||Retribution||19|
|APNewsBreak: Problems remain at troubled Washin...||1 hr||CodeTalker||1|
|After three days the South Carolina Senate leav...||11 hr||Lady Rivera||1|
|Nurse anesthetists aren't the same as anesthesi... (Sep '10)||12 hr||Stanley||143|
|Any side effects while on Chantix? (Jul '07)||14 hr||Keith sluder||1,745|
|Community activities, meetings (Jul '09)||Fri||Grandparent in Mi...||5|
|Chantix dosage - 2mg to start off? (Sep '07)||Apr 20||RCKilgore||50|
Find what you want!
Search Healthcare Law Forum Now
Copyright © 2017 Topix LLC